千亿·国际(中国)唯一官方网站
Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
A-Share Information
H-Share Information
2025.06.17
千亿国际：关于依诺肝素钠注射液获得EMA新增生产商批准的公告
2025.05.23
POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING HELD ON MAY 22, 2025
2025.05.23
千亿国际：2024年年度股东大会决议公告
2025.04.30
2024 AGM Circular
2025.04.30
2024 Environmental, Social and Governance Report
2025.04.30
2024 Annual Report
2025.04.25
VOLUNTARY ANNOUNCEMENT “IVENOXIN” OBTAINS APPROVAL FROM SOUTH AFRICA
2025.04.25
2025 FIRST QUARTERLY REPORT
2025.04.24
千亿国际：监事会决议公告
2025.04.24
千亿国际：关于依诺肝素钠注射液获得南非药品注册批件的公告
第一页
上一页
1
2
3
4
5
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
